糖化白蛋白和复合糖血脂指数:用于诊断2型糖尿病的补充工具
Vera Lukić1, Ana Ninić2, Gordana Džingalašević3
1Department of Laboratory Diagnostics, Railway Healthcare Institute, 11000 Belgrade, Serbia.
Journal of biomedical research
|November 21, 2025
概括
糖化白蛋白 (GA) 和糖化血红蛋白 (HbA1c),特别是当与高密度胆固醇 (HDL-C) 结合时,显示出2型糖尿病 (T2DM) 的诊断效用. 在塞尔维亚人口中,GA/HDL-C指数为T2DM检测提供了高特异性.
科学领域:
- 临床生物化学 临床生物化学
- 内分泌学 在内分泌学.
- 糖尿病研究 糖尿病研究
背景情况:
- 糖化白蛋白 (GA) 是一种新兴的血糖生物标志物,与糖化血红蛋白 (HbA1c) 相比,它具有优势,特别是在影响红细胞周转的条件下.
- 2型糖尿病 (T2DM) 经常与葡萄糖和脂质代谢的同时障碍有关.
- 评估T2DM诊断的新生物标志物和复合指数对于有效的患者管理至关重要.
研究的目的:
- 评估GA,HbA1c及其复合指数与高密度脂蛋白胆固醇 (HDL-C) 在塞尔维亚队列中的诊断效用.
- 调查T2DM的GA/HDL-C和HbA1c/HDL-C比率的综合诊断性能.
- 为塞尔维亚人口建立参考GA数据.
主要方法:
- 对124名塞尔维亚成年人 (T2DM患者和健康对照) 的GA,HbA1c,葡萄糖和脂质资料的分析.
- 复合指数的计算:GA/HDL-C 和 HbA1c/HDL-C.
- 应用后勤回归和接收器操作特征 (ROC) 曲线分析来确定诊断性能.
主要成果:
- 与对照组相比,T2DM患者的GA和HbA1c水平显著提高,HDL-C水平降低.
- 无论是GA/HDL-C还是HbA1c/HDL-C都显示出与T2DM有很强的关联.
- HbA1c在0.966的曲线下面积 (AUC) 产生了最高的结果,其次是HbA1c/HDL-C (0.883),GA/HDL-C (0.859) 和GA (0.855).
- 该GA/HDL-C指数达到92.06%的高特异性.
结论:
- 糖化白蛋白作为T2DM诊断的有价值的补充生物标志物.
- 像GA/HDL-C和HbA1c/HDL-C这样的复合指数提高了诊断特异性,并为综合代谢风险评估提供了成本有效的方法.
- 这项研究为塞尔维亚队列提供了第一个GA数据,有助于更广泛的临床适用性.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
Diabetes: Management and Pharmacotherapy
851
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
851
Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567


